1 Covid stock I’d consider for my ISA

Zaven Boyrazian looks at how the pandemic is forcing hospitals to improve cleaning practices, and a Covid stock ready to take advantage of this shift.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since the Covid-19 pandemic began we’ve endured a vast amount of disruption to everyday life and hospitals have seen a surge of additional pressure. Due to the highly infectious nature of the virus, hospitals are having to put in place more rigorous cleaning and disinfecting practices, something that has greatly benefited this ‘Covid stock’.

The Covid stock opportunity

Tristel (LSE:TSTL) manufactures infection prevention, contamination control, and hygiene products. Its leading technology is a proprietary chlorine dioxide solution that it incorporates into its high-performance disinfectants.

The business model is relatively simple. Tristel creates and sells its portfolio of disinfectant products to hospitals and veterinary clinics under three different brands – Tristel, Anistel and Crystel.

It has also begun building a new brand – Cache. It’s an offshoot of the Tristel brand that will specialise solely in surface disinfection for hospitals.

Since each product is fundamentally a consumable for medical institutions, it creates a continuous need to repurchase the same product frequently. Given the difficulty of receiving approval for such products from regulators, the selection pool for hospitals is very narrow, reducing the brand’s active competition.

The business

Revenue Breakdown £m Brand 2019 2020
Medical Device Decontamination (Hospitals) Tristel 20.8 35.5
Environmental Surface Decontamination (Hospitals) Cache 2.6 4.9
Other (Hospitals & Veterinary Clinics) Crystel, Anistel, Miscellaneous 2.8 3.3

The firm’s leading source of revenue derives from its Medical Device Decontamination (MDD) line of products. It’s expected to continue growing organically from the introduction of a new ultrasound probe disinfectant set to launch in Q2 2021.

However, the management team has identified an underlying trend in its Environment Surface Decontamination (ESD) line of products. The aftermath of Covid-19 is expected to result in new legislation that will most likely require hospitals to rigorously improve their cleaning and disinfection practices.

In the four months leading up to June 2020, it saw a rapid increase in the consumption of its ESD products. This trend is expected to increase as the year progresses, improving its revenue streams.

The financials

£m 2020 2019 2018 2017 2016
Revenue 32 26 22 20 17
Operating Profit 6.8 4.7 4.0 3.9 2.6
Operating Profit Margin (%) 21.3 18.1 18.1 19.5 15.1
Return on Equity (%) 18.2 17.5 18.2 21.4 14.0

The stock has achieved an impressive top-line revenue growth rate of 17% year-on-year for the past five years that has primarily been driven by international sales. While certainly rewarding shareholders, this dependence on overseas trade introduces a considerable currency exchange rate risk. That’s because it has resulted in almost 60% of revenues being generated outside the UK.  

Operating profit has also seen double-digit growth of 28% year-on-year courtesy of improved margins as the firm streamlines its operations.

These growth rates combined have allowed shareholders to reap a sizable return on equity as well as a 360% increase in the share price over the same period.

It all sounds good for this particular Covid stock, but with a P/E ratio of just over 40, the stock is certainly not cheap.

Since 2019 the price has appreciated by 49%. However, this return appears to be primarily driven by shareholder expectations of future performance. Therefore it’s likely to see short-term price volatility if earnings don’t meet expectations over the next few quarters.

The bottom line

With the firm seeking FDA approval of its products early next year, it could open up the entire US medical market to it for operational expansion. I think this growth opportunity, combined with the rising demand for disinfection products caused by the pandemic, makes the high valuation justified, and this a Covid stock worthy of consideration.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Tristel. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »